CHICAGO, IL—The addition of spironolactone, a mineralocorticoid receptor antagonist, to usual care significantly reduced systolic and diastolic blood pressure (BP) in patients with a prior stroke, according to results of the REDUCE trial.
Presented recently at the American Heart Association 2026 Scientific Sessions, adding spironolactone reduced systolic BP by a mean of 7.7 mmHg at 3 months when compared with standard care in patients with a prior ischemic or hemorrhagic stroke, reported Jordana Cohen, MD (University of Pennsylvania Perelman School of Medicine, Philadelphia).
“We know that blood pressure control after stroke is suboptimal,” said Cohen during a press briefing. “[Elevated] blood pressure is defined in the guidelines as the most important modifiable risk factor for recurrent stroke and yet we don’t do a good job managing it.”
The US guidelines recommend that clinicians treat to a target of less than 130/80 mmHg in patients with a prior ischemic stroke or transient ischemic attack. In Europe, the guidelines make a similar recommendation, stating that doctors should aim for a systolic goal of 120 to 129 mmHg, if tolerated. Cohen said that while the target is clear, “we don’t have great evidence guiding what to do and how to get us there in terms of treatment selection, in terms of what approaches we should be taking.”
Marc Bonaca, MD (University of Colorado School of Medicine, Aurora), the discussant following the late-breaking presentation, questioned whether it’s time to adopt a more aggressive treatment approach before patients leave the hospital after stroke.
“Almost nothing has happened over two decades in terms of the utilization of antihypertensive medications in this population,” said Bonaca. “There’s a big implementation gap.” Patients are going home with uncontrolled hypertension, and “what we’ve learned is that if they don’t leave the hospital on therapy, it’s not going to get started.”
Most Patients Randomized in First Year After Stroke
Data from the PATHWAY-2 study, published more than a decade ago, showed that spironolactone was an effective add-on therapy in patients with resistant hypertension who required four medications. However, spironolactone hasn’t been tested in patients on fewer antihypertensive drugs, or in the post-stroke patient who often has significant upregulation of the renin-angiotensin-aldosterone system (RAAS), said Cohen.
The REDUCE trial was conducted at 5 US centers and included 160 adults with a prior ischemic or hemorrhagic stroke and systolic BP of 120-200 mmHg based on a run-in period of home blood pressure monitoring. REDUCE included a diverse population, with Black and Hispanic participants making up 30% and 16% of the study, respectively. Patients with moderate-to-severe kidney disease and clinically significant hyperkalemia were excluded from the study.
In all, 85 patients (mean age 64.4 years; 33% female) were randomized to spironolactone 25 mg, uptitrated to 50 mg at 2-4 weeks, added to usual care and 75 patients (mean age 61.8 years; 43% female) were randomized to usual care alone. Most patients were enrolled in the first year after a stroke, although there were a small number outside this window. At baseline, the mean home systolic BP in both groups was 136 mmHg. Patients were taking 1.8 and 2.0 antihypertensive medications in the spironolactone- and usual-care study arms.
We know that blood pressure control after stroke is suboptimal.
Jordana Cohen, MD
At 3 months, the mean systolic BP was 133.3 mmHg in the usual-care arm versus 125.6 mmHg in the spironolactone group (mean difference 7.7 mmHg; P = 0.0002). The difference persisted to 6 months: 130.9 versus 124.0 mmHg in the usual-care and spironolactone groups (mean difference 6.9 mmHg; P = 0.0004). The mean difference in diastolic BP at 3 months was 4.1 mmHg favoring spironolactone. Overall, 52% of patients treated with spironolactone achieved the recommended target of less than 130/80 mmHg at 3 months compared with 30% treated with usual care (P = 0.01).
In the subgroup who received spironolactone within 90 days of the index stroke, home systolic BP at 3 months was 13.0 mmHg lower than with usual care. Similarly, the subgroup with a body mass index 30 kg/m2 or higher had larger reductions in systolic BP with spironolactone compared with usual care.
Cohen pointed that those randomized to usual care rarely had their medication changed during the 6-month study period.
“Despite blood pressure being above the recommended targets, the usual-care arm had almost complete inertia,” she said. “There was almost no intensification of blood pressure management in that group, which was quite problematic and concerning in terms of how we’re managing stroke in this population.”
Is It BP or Is It Spironolactone?
Bruce Ovbiagele, MD (University of California, San Francisco), an AHA spokesperson and neurologist, said there is data showing that roughly one-third of stroke survivors aren’t treated to the guideline-recommended target of less than 130/80 mmHg. Also, more than 20% of post-stroke patients stop their medications in the first year. While BP control is important for all stroke patients, patients with intracerebral hemorrhage (ICH) “really need to address blood pressure control after the index event.”
RECAP-ICH, a meta-analysis of nearly 3,000 patients, showed that intensive BP lowering after ICH reduced the risk of recurrent stroke by 38% without an increase in serious adverse events. Similarly, TRIDENT showed that a low-dose, triple-combination antihypertensive therapy reduced the risk of recurrent stroke by 39% after ICH.
There’s a tension between treating aggressively upfront or titrating dosing over time, said Bonaca. The PROVE-IT trial, conducted in acute coronary syndrome patients, changed practice as it showed that an intensive strategy with a high-intensity statin improved clinical outcomes. The 7.7-mmHg difference in systolic BP with the addition of spironolactone also has the potential to improve outcomes.
“I would say that, for me, seeing the fact that these patients got started on medication—versus in the usual-care arm where they didn’t—was probably the most important feature,” said Bonaca. “Spironolactone is a good drug, but maybe it’s just treating the blood pressure or having a plan before they leave.”
Ovbiagele said REDUCE will be helpful but should be considered proof-of-concept at this point, noting that it “provides compelling evidence that informs, but not quite defines, clinical practice.” The study is small, for one, and there is little clarity on whether the reduction in BP resulted from treatment intensification alone or if RAAS inhibition is particularly relevant in these patients.
Source:
Cohen J, on behalf of the REDUCE investigators. REDUCE: a randomized, controlled trial of spironolactone-based blood pressure management after stroke. Presented at the American Heart Association Scientific Sessions, November 7, 2026.
Disclosures:
Cohen, Ovbiagele, and Bonaca report no conflicts of interest.
